Erythropoietin produced in a human cell line (Dynepo) has significant differences in glycosylation compared with erythropoietins produced in CHO cell lines

摘要: Recombinant human erythropoietin has been used to treat anemia associated with chronic renal disease. This paper provides a comprehensive comparative analysis of Dynepo and three other commercial erythropoiesis stimulating agents, Eprex, NeoRecormon Aranesp. We found significant differences in the type, levels amount O-acetylation sialic acids. Sialic acids present provide protection from clearance circulation. Aranesp had up six O-acetyl groups attached Eprex only minor amounts while none. no Neu5Gc, which is potentially immunogenic for humans. contained least disialylated highest tetrasialylated glycans. more trisialylated, but less glycans than tetraantennary lowest triantennary β1-6-GlcNAc linkage...